[68Ga]Ga-DOTA-TATE

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

GlioblastomaMetastatic Neuroendocrine Prostate Cancer

514 competitors in Glioblastoma

#DrugCompanyPhaseTrials

1

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1612

Ceenu

AAzurity Pharmaceuticals

Phase 3

223

Gleevec

Novartis

Phase 3

24

Scemblix

Novartis

Phase 3

15

Cymbalta

Alnylam Pharmaceuticals

Phase 3

16

Feraheme

AAzurity Pharmaceuticals

Phase 3

47

Zejula

GGlaxo Dba Glaxosmithkline

Phase 3

48

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

49

Droxia

TTheravia

Phase 3

310

Paraplatin

AAvyxa

Phase 3

3Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metastatic Neuroendocrine Prostate Cancer1 trial

A Phase I, Open-label, Multi-center Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting·Novartis·Phase 1·NCT06379217·31 enrolled

Glioblastoma1 trial

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent

Active, not recruiting·Novartis·Phase 1·NCT05109728·55 enrolled

Details

Drug Info

Related News